^




Show legend
Group by Gene:
Include preclinical:

Mvasi (bevacizumab biosimilar)
0
VEGF-A inhibitor
Bevax (bevacizumab biosimilar)
bevacizumab
Zirabev (bevacizumab biosimilar)
1
PD1 inhibitor
dostarlimab
pembrolizumab
2
Thymidylate synthase inhibitor, Topoisomerase I inhibitor
5-fluorouracil + irinotecan
3
DNA synthesis inhibitor, DNA cross linking agent
oxaliplatin
4
Topoisomerase I inhibitor
irinotecan
5
Thymidylate synthase inhibitor
capecitabine
5-fluorouracil
cetuximab
6
EGFR inhibitor
panitumumab
ABP 494 (cetuximab biosimilar)
7
TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
larotrectinib
8
FGFR inhibitor
Debio 1347
9
RET inhibitor
selpercatinib
pralsetinib
10
PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab
11
ALK inhibitor, Multi-tyrosine kinase inhibitor
crizotinib + pazopanib
FOLFOX
12
Chemotherapy
mFOLFOX6
FLOX
CAPOX
13
Immunotherapy
Immunotherapy
14
CDK9 inhibitor
CDK9 inhibitor
15
DNA synthesis inhibitor, DNA cross linking agent, Folate analog, Thymidylate synthase inhibitor
5-fluorouracil + oxaliplatin + leucovorin calcium
16
HER2-targeted antibody-drug conjugate, Microtubule inhibitor
ado-trastuzumab emtansine
17
BRAF inhibitor, EGFR inhibitor
cetuximab + vemurafenib
18
pan-RAF inhibitor, EGFR inhibitor, Multi-tyrosine kinase inhibitor
cetuximab + sorafenib
19
PD-L1 inhibitor, IL-15R stimulant
KD033
20
COX2 inhibitor, Ca2+ channel antagonist
amlodipine / celecoxib
21
PI3K inhibitor
BKM120
22
MEK inhibitor
binimetinib
trametinib
23
Trk inhibitor
FCN-098
24
PI3K inhibitor, mTOR inhibitor, mTORC1 inhibitor, mTORC2 inhibitor
PF-05212384
25
Microtubule inhibitor
eribulin mesylate
26
MEK inhibitor, PI3K inhibitor, mTOR inhibitor, mTORC1 inhibitor, mTORC2 inhibitor
PF-05212384 + PD-0325901
27
PARP2 inhibitor, PARP inhibitor
talazoparib
28
PD-L1 inhibitor
CCX559
29
MEK inhibitor, BRAF inhibitor
trametinib + dabrafenib
CS-1018
30
STING agonist
CS-1010
CS-1020
31
BRAF inhibitor
ABM-1310
32
BCAT1 inhibitor
ERG 245
33
DNA synthesis inhibitor
cisplatin
34
E3 ubiquitin-ligase hakai inhibitor
Hakin-1
35
Tubulin polymerization promoter
paclitaxel
No biomarker
MSI-H/dMMR
miR-31-5p underexpression
BRAF V600E
BRAF mutation
BRAF V600
RET fusion
POLE A456P
POLE V411L
PMS2 negative
FGFR2 fusion
FGFR2-INA fusion
BRIP1 mutation
RAD50 mutation
ATR mutation
BRCA2 mutation
ATM mutation
HER-2 positive
NTRK3 fusion
NTRK1 fusion
RAF1 R256S
NTRK2 fusion
ALK R1209Q
EGFR L858R
EGFR E709K
EGFR P596L
EGFR R222C
EGFR R165Q
EGFR E114K
EGFR G63R
EGFR K708R
BCAT1 expression
KLF4 overexpression
CDH1 expression
FBXW7 overexpression
PD-L1 negative
PD-L1 expression
KRAS G12R
ETV5 overexpression
MAP2K1 K57T
SIRT6 underexpression
AREG expression
FGFR4 expression
KRAS N116H
KRAS N116T
KRAS Q22X
MAP2K1 V211D
TPM3-NTRK1 G595R
ETV6-NTRK3 G623R
PIK3CA H1047R
KRAS mutation
TP53 mutation
SMAD4 mutation
ABCB1 expression
KRAS G13D
EGFR G719S
KRAS G12V
PIK3CA mutation
ARID1A deletion
miR-375 expression
miR-199a-5p expression
MLH1 deletion
TERT mutation + BRAF V600E
EGFR G724S
CIC deletion
STING mutation
LMNA-NTRK1 G667C